Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

OBJECTIVES: Primary * To establish the safety profile and the maximum tolerated dose of the combination of cisplatin, paclitaxel, and everolimus in patients with metastatic breast cancer. Secondary * To explore the antitumor activity of this regimen, in terms of response rate and time to progression in these patients. OUTLINE: This is a multicenter study. Patients receive cisplatin intravenously (IV) over 1 hour and paclitaxel IV over 1 hour on days 1, 8, and 15. Patients receive oral everolimus on days 1, 8, 15, and 21. Courses repeat every 4 weeks in the absence of disease progression and unaccepted toxicity. After completion of study therapy, patients are followed at 4 weeks.